AbbVie again extends Pharmacyclics offer; India high court blocks Glenmark's Januvia, Janumet knockoffs;

@FiercePharma: J&J nears $7.5M deal in Risperdal case that could have cost $1.2B. Report | Follow @FiercePharma

@EricPFierce: FDA blesses Baxter saline plant in Spain for shipments to U.S. of 0.9% sodium chloride. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Perrigo will talk tie-up if the price is right, CEO says--but Mylan has a ways to go. Report | Follow @CarlyHFierce

> AbbVie ($ABBV) once again extended its tender offer for Pharmacyclics ($PCYC) stock, to Friday afternoon, as it seeks to wrap up its $21 billion purchase of the company. Report

> India's Supreme Court barred the domestic generics maker Glenmark Pharmaceuticals from selling its knockoffs of Merck & Co.'s ($MRK) diabetes drugs Januvia and Janumet, though the company can sell off existing inventory. Report

> In selling Par Pharmaceutical to Endo ($ENDP) for $8 billion, the private equity firm TPG pulled off a big gain: up to 7 times its initial equity investment in the generics maker. Report

> Retailer Meijer sued India-based Ranbaxy Laboratories over the generics maker's delays in producing copycat versions of branded meds Diovan, the Novartis ($NVS) hypertension remedy, and Valcyte, the Roche ($RHHBY) antiviral. Report

> Philadelphia-based drugmaker Lannett ($LCI) shelled out $42 million in cash to buy privately held Silarx Pharmaceuticals. Report

> In India, Fresenius Kabi Oncology challenged a Wyeth patent for Torisel (temsirolimus)--an injectable for treating renal cancer--saying that temsirolimus already was known in India before Wyeth claimed to have invented it. Report

Medical Device News

@FierceMedDev: UPDATED w/ interview: Apollo's minimally invasive intragastric weight-loss balloon shows promise in clinical trial. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Advice for med tech entrepreneurs: Identify your customer and consider stakeholders' incentives carefully. Editor's corner | Follow @VarunSaxena2

@EmilyWFierce: $ILMN filed a patent infringement suit against Ariosa/$RHHBY over prenatal testing tech. Release | Follow @EmilyWFierce

> Silk Road scores FDA approval for less invasive stent system. Story

> NEA startup ClarVista gets $14.5M to gain CE mark for intraocular lens. Article

Biotech News

@FierceBiotech: ICYMI: Novo's liraglutide works in diabetes and obesity. How about NASH? More | Follow @FierceBiotech

@JohnCFierce: Got a few personal notes and saw at least 1 Twitter campaign linked to our "Influentials' list. Check out the report. Feature | Follow @JohnCFierce

> PsiOxus bags $39M from Woodford, GSK for checkpoint inhibitor combo trial. Story

> Intercept plots a big Phase III NASH trial with room for an early approval. Report

> Bluebird beats a path to early approval for its pioneering gene therapy. Article

Drug Delivery News

> 'Nanosponges' held in place with a hydrogel absorb toxins in MRSA infections. Story

> Study finds testosterone gels and patches safer than injections. More

> Endo to buy Par Pharma for $8B to bulk up in injectables. Item

> Celyad, formerly Cardio3, files for U.S. IPO worth up to $115 million. Article

> FDA approves pediatric version of Treximet to treat migraines. Report

Pharma Manufacturing News

> Pharmaniaga project in Saudi Arabia stalls but others move forward. More

> Janssen gets Rutgers' help in move to continuous manufacturing. Article

> FDA blesses Baxter saline plant in Spain to produce for U.S. More

> J&J donates $6M to Rutgers, which is helping Janssen move to continuous manufacturing. Story

> AstraZeneca says Sweden getting its new $285M biologics plant. Report

Pharma Asia News

> Wockhardt faces long haul on FDA travails, Business Today says. Story

> India's Zydus Cadila has 10 vaccines in development, set to launch next year. More

> India drug IP laws in spotlight again in local Fresenius Kabi-Pfizer case. Article

> Taiwan recalls batches of injectable sodium chloride made by Y.F. Chemical. Report

> Thailand faces pushback from private hospitals on cost claims. Item

And Finally... Dense breast tissue isn't necessarily a risk for breast cancer, a new study found. Report (sub. req.)

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.